Carcinoma clinical trials in Boston

Pembrolizumab with or without chemotherapy for stage IV lung cancer

This trial tests whether pembrolizumab alone, or pembrolizumab plus chemotherapy, can treat stage IV non-small cell lung cancer. It may help shrink tumors and improve outcomes by boosting the immune system, with or without added chemotherapy.

Testing cetuximab plus pembrolizumab for advanced head and neck cancer

This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).

Drug screening for skin squamous cell cancer lesions

This trial tests a device placed on skin cancer lesions to see which drugs might work best. It is for people with visible squamous cell carcinoma on the skin, including lesions that have come back after radiation.

Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer

This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.

Study of REM-422 for advanced adenoid cystic carcinoma

This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.

KO-2806 for advanced solid tumors

This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.

Gene study for kids with pancreas problems

This study collects samples like blood or tissue from children with pancreatitis to look for gene changes that might raise their risk. It helps doctors learn more about why some children get pancreas inflammation.

T cell activator STAR0602 for advanced solid tumors

This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.

ctDNA surveillance for HPV-negative head and neck cancer

This trial uses a blood test to look for tiny bits of tumor DNA after treatment for head and neck cancer. It aims to see if this test can detect any remaining cancer cells early, so you and your doctor can make informed decisions.

Study of AB521 for kidney cancer and other solid tumors

This early-stage trial tests AB521, alone and in combination with other medicines, in people with advanced solid tumors—especially clear cell kidney cancer. It aims to find a safe dose and see whether the treatment could help shrink tumors or control the disease.

A Study of Sovilnesib in Subjects With Ovarian Cancer

Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer

This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.

Adding targeted tumor treatment to standard therapy for limited metastatic colorectal cancer

This trial tests whether adding a precise, targeted treatment to destroy remaining cancer spots (called total ablative therapy) after initial chemotherapy can improve outcomes for people with limited metastatic colorectal cancer. It aims to see if this extra treatment is safe and effective.

Adding immunotherapy to radiation for bladder cancer

This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.

Study of BL-M07D1 for HER2-positive solid tumors

This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.

Study of ANK-101 for advanced solid tumors

This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.

Exercise during chemo to prevent weakness from low movement

This study tests whether a structured exercise program during chemotherapy can help prevent physical decline (“immobility,” like getting weaker or moving less) in people with certain ovarian or endometrial cancers. If you’re eligible, you may be guided to exercise while receiving standard chemo, and you’ll have blood tests to track changes.

Avelumab and M1774 for ARID1A-mutated endometrial cancer

This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.

Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer

This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.

Ivonescimab for advanced salivary gland cancer

This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.

Trastuzumab deruxtecan with or without anastrozole for early breast cancer

This Phase 2 study tests whether trastuzumab deruxtecan alone or combined with anastrozole can control early-stage breast cancer that is HER2-low and hormone-receptor positive. It aims to improve outcomes after initial surgical treatment by targeting cancer cells that may have low levels of HER2.

Cemiplimab injection for early-stage skin cancer

This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.

Study of NKT3964 for advanced solid tumors

This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.

Testing an anti-cancer drug alone and with pembrolizumab

This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.